Grant: Discovery Grants Program - Individual
University of British Columbia
$36,000.00
Discovery of novel inhibitors of Toll-like receptor signaling.
FY 2017-18
Summary
GENERAL OBJECTIVES: The overarching goal of this research program is to empower the identification of new molecules to inhibit Toll-like receptor signaling.BACKGROUND: The integrated host defense system of most vertebrates has two branches: innate and adaptive (or acquired) immunity. Understanding of innate immunity was accelerated in the mid-1990s when the Drosophila protein Toll was shown to be critical for defending fruit flies against infections. This opened the way for the description of similar proteins, called Toll-like receptors (TLRs), in mammalian cells. TLRs allow for recognition and response to diverse microbial epitopes-pathogen-associated molecular patterns or PAMPs-enabling the innate immune system to induce an appropriate cascade of effector responses.The innate immune system and TLR signaling play a vital role in protection from infections. However, TLR signaling is a 'double-edged sword' and vigorous innate immune responses can be harmful contributing to pathology in both animal and human diseases. Today there are very few compounds available to inhibit TLR signaling and this research program is designed to address this fundamental knowledge gap. RESEARCH PLAN: With the goal of identifying and characterizing new inhibitors of TLR signaling, I have partnered with Dr Raymond Andersen (Chemistry, UBC) to establish a high-throughput platform to screen crude marine sponge extracts for novel, potent TLR inhibitors. To date we have identified several potent and non-cytotoxic novel TLR inhibitors, including girolline. Within the 5 year scope of this current funding request, we will address the following fundamental research questions: (a) Can we identify and validate more novel TLR inhibitors from natural marine sponge products?; (b) Through comprehensive structure-activity relationship (SAR) studies, can we develop compounds that are more potent, less toxic and easy to synthesize?; and (c) Can we define the mechanism(s) of action of the TLR inhibitors?
Program
Discovery Grants Program - Individual
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
435829-2013
Name nom
Turvey, Stuart
Department département
Pediatrics
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2013
Award amount
36000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Partie
5
Nb partie
5
Application title
Discovery of novel inhibitors of Toll-like receptor signaling.
Keyword
NSERC
Application summary
GENERAL OBJECTIVES: The overarching goal of this research program is to empower the identification of new molecules to inhibit Toll-like receptor signaling.BACKGROUND: The integrated host defense system of most vertebrates has two branches: innate and adaptive (or acquired) immunity. Understanding of innate immunity was accelerated in the mid-1990s when the Drosophila protein Toll was shown to be critical for defending fruit flies against infections. This opened the way for the description of similar proteins, called Toll-like receptors (TLRs), in mammalian cells. TLRs allow for recognition and response to diverse microbial epitopes-pathogen-associated molecular patterns or PAMPs-enabling the innate immune system to induce an appropriate cascade of effector responses.The innate immune system and TLR signaling play a vital role in protection from infections. However, TLR signaling is a 'double-edged sword' and vigorous innate immune responses can be harmful contributing to pathology in both animal and human diseases. Today there are very few compounds available to inhibit TLR signaling and this research program is designed to address this fundamental knowledge gap. RESEARCH PLAN: With the goal of identifying and characterizing new inhibitors of TLR signaling, I have partnered with Dr Raymond Andersen (Chemistry, UBC) to establish a high-throughput platform to screen crude marine sponge extracts for novel, potent TLR inhibitors. To date we have identified several potent and non-cytotoxic novel TLR inhibitors, including girolline. Within the 5 year scope of this current funding request, we will address the following fundamental research questions: (a) Can we identify and validate more novel TLR inhibitors from natural marine sponge products?; (b) Through comprehensive structure-activity relationship (SAR) studies, can we develop compounds that are more potent, less toxic and easy to synthesize?; and (c) Can we define the mechanism(s) of action of the TLR inhibitors?